← Leaderboards
James Blackledge
Capella Imaging, Llc
$1,849,713
Attributed
$2,674,075
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2017–23$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,674,075 · 2
By mechanism
R42$2,674,075 · 2
Top collaborators
- Gregory M Lanza3 shared
Others in their field
Other Emerging Leaders on “Cessation Of Life”
- Xinhua Li · Nano Terra, Inc.$32,520,955
- Christopher Barnaby Nelson · University Of Melbourne$27,954,628
- Abraham Aizer Brody · New York University School Of Medicine$21,799,826
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$20,810,724
- Jeffrey Reich · Sparian Biosciences, Inc.$20,633,040
- Beth Baseler · Leidos Biomedical Research, Inc.$18,109,529
Research focus
Cessation Of LifeSerumSmall Business Technology Transfer ResearchBiological MarkersDiagnosisImageDetectionAnalytical ChemistryChemical SynthesisChemistryAcuteAreaAvidityBenchmarkingCannulasAgedCardiologyBlood FlowBlood SpecimenAnimalsAnticoagulationAcute Kidney FailureAntiplatelet DrugsBiomedical Engineering
Grant awards (4)
Development and Commercialization of a New Molecularly Targeted Imaging Agent for Multiple Myeloma$1,025,350
R42 · FY2023 · CA · contact PI
Development of Fibrin-Specific Nuclear Probe to Reduce LVAD Adverse Events$728,200
R42 · FY2019 · HL · contact PI
Development of Fibrin-Specific Nuclear Probe to Reduce LVAD Adverse Events$768,622
R42 · FY2018 · HL · contact PI
Development of Fibrin-Specific Nuclear Probe to Reduce LVAD Adverse Events$151,903
R42 · FY2017 · HL · contact PI